Testing a new combination treatment for advanced pancreatic cancer

Plain-English translation of NCT07114861 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called KN510713 combined with a standard chemotherapy treatment called mFOLFIRINOX in patients with advanced pancreatic cancer that cannot be surgically removed. Researchers want to find the safest and most effective dose of the medication and understand how well this combination works compared to chemotherapy alone. The study will help determine if adding this new treatment improves outcomes for people with this serious disease.

Pancreatic cancer is very difficult to treat, and people with advanced disease need better treatment options. This trial exists because researchers believe that this new medication may work better when combined with standard chemotherapy, potentially helping patients live longer and healthier lives.

Do you qualify?

You likely qualify if…

you are between 19 and 75 years old
you have been diagnosed with advanced pancreatic cancer that cannot be surgically removed and have not yet received chemotherapy for this advanced disease
you have measurable cancer that can be seen on imaging scans
you are in good enough health to tolerate treatment, with a life expectancy of at least 12 weeks
your blood work shows adequate kidney, liver, and bone marrow function
you have not had major surgery within the past 4 weeks

You likely don't qualify if…

you have a known allergy or severe sensitivity to this medication or similar drugs
you have had another type of cancer within the past 5 years (with some exceptions for skin cancers)
you have had a recent heart attack, unstable chest pain, or severe heart failure within the past 6 months
you have a genetic condition called DPD deficiency or carry certain genetic variations in the UGT1A1 gene that affect how your body processes chemotherapy
you have moderate to severe nerve damage, chronic diarrhea, bowel obstruction, or severe lung disease

What participation looks like

As a participant, you would receive the new medication (KN510713) at one of two different dose levels combined with standard chemotherapy (mFOLFIRINOX) through regular clinic visits. The trial has two phases: first, doctors will test different doses to find the safest amount, and then they will expand the study to treat more patients at that dose. You would have regular blood tests and scans to monitor how the treatment is working and check for side effects throughout your participation.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

South Korea

National Cancer Center, Goyang-si